Norstella’s VP of thought leadership discusses why pharma spent more on R&D, got fewer drugs, and is heading toward a $500 billion patent cliff unprepared.
Dan Chancellor
Advertisement
Dan Chancellor is VP of thought leadership of Norstella.
Articles by Dan Chancellor
Advertisement
Latest Updated Articles
Advertisement
Advertisement